FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

In our exclusive interview, Aditya Bardia, MD, of Massachusetts General Hospital Cancer Center, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer, the implications of the approval, and ongoing research with the agent.